Log In
Print this Print this

AR-401 (formerly KBAB401)

  Manage Alerts
Collapse Summary General Information
Company Aridis Pharmaceuticals Inc.
DescriptionHuman antibody against Acinetobacter baumanii generated using the MabIgX platform technology
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationBacterial infection
Indication DetailsTreat Acinetobacter baumanii infections
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today